Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, HC Wainwright Analyst Says

Eton Pharmaceuticals (NASDAQ:ETON) had its price target raised by equities researchers at HC Wainwright from $37.00 to $52.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 129.23% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Craig Hallum raised their price objective on Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, B. Riley Financial upped their price target on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $39.33.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON traded up $1.92 during mid-day trading on Friday, reaching $22.69. 523,179 shares of the company’s stock were exchanged, compared to its average volume of 282,471. The business’s fifty day simple moving average is $16.59 and its two-hundred day simple moving average is $17.34. Eton Pharmaceuticals has a one year low of $11.09 and a one year high of $23.00. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. The firm has a market capitalization of $608.41 million, a PE ratio of -90.74 and a beta of 1.19.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, March 19th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative net margin of 9.50% and a negative return on equity of 11.32%. The firm had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. Analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ETON. State of Alaska Department of Revenue bought a new stake in Eton Pharmaceuticals during the 3rd quarter valued at approximately $30,000. Ameritas Investment Partners Inc. purchased a new position in Eton Pharmaceuticals in the second quarter worth about $37,000. Quarry LP bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Legal & General Group Plc purchased a new stake in shares of Eton Pharmaceuticals in the second quarter valued at $41,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at approximately $44,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Analysts’ price targets show substantial upside — the mean target implies roughly a 49% upside versus the current share price, and Zacks notes analyst upgrades in estimates that can support further gains. Read More.
• Positive Sentiment: Revenue strength / record top‑line growth: Eton reported record Q4 revenue and beat consensus revenue estimates modestly, which supports the narrative of accelerating commercial traction in its rare‑disease portfolio. Read More.
• Neutral Sentiment: Earnings call materials and summaries are available for investors to assess management’s commentary on growth drivers and commercialization plans. Review the call summary for color on guidance and product rollouts. Read More.
• Neutral Sentiment: The full earnings call transcript is posted for detailed read‑through of management’s remarks and Q&A, useful for judging sustainability of revenue trends. Read More.
• Negative Sentiment: EPS miss and ongoing unprofitability: Eton reported $0.05 EPS versus a $0.12 consensus (miss of $0.07) and still posts a negative net margin and negative ROE, highlighting that profitability and cost control remain concerns despite revenue growth. Read More.
• Negative Sentiment: Analysts and media flagged the EPS shortfall in standalone coverage, which can weigh on near‑term sentiment even as estimates get revised upward. Read More.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.